126 related articles for article (PubMed ID: 1606291)
1. Fibrinolysis and fibrinogenolysis in patients with thrombotic disease.
Takahashi H; Wada K; Hanano M; Niwano H; Takizawa S; Yazawa Y; Shibata A
Blood Coagul Fibrinolysis; 1992 Apr; 3(2):193-6. PubMed ID: 1606291
[TBL] [Abstract][Full Text] [Related]
2. Fibrinolysis and fibrinogenolysis in disseminated intravascular coagulation.
Takahashi H; Tatewaki W; Wada K; Niwano H; Shibata A
Thromb Haemost; 1990 Jun; 63(3):340-4. PubMed ID: 2402738
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolysis and fibrinogenolysis in liver disease.
Takahashi H; Tatewaki W; Wada K; Niwano H; Shibata A
Am J Hematol; 1990 Aug; 34(4):241-5. PubMed ID: 2195867
[TBL] [Abstract][Full Text] [Related]
4. [Differentiation between fibrin degradation products and fibrinogen degradation products by using newly developed ELISAs].
Isogai N; Yamagishi T; Kaku M; Matsumoto K; Yamamoto Y; Kuroso K; Arai M; Yorifuji H; Fukutake K; Fujimaki M
Rinsho Byori; 1991 Jul; 39(7):753-7. PubMed ID: 1920869
[TBL] [Abstract][Full Text] [Related]
5. Implications of fibrinogenolysis in patients with closed head injury.
Kushimoto S; Shibata Y; Yamamoto Y
J Neurotrauma; 2003 Apr; 20(4):357-63. PubMed ID: 12866815
[TBL] [Abstract][Full Text] [Related]
6. Correlations between plasma levels of fibrin(ogen) derivatives as quantified by different assays based on monoclonal antibodies.
Kroneman H; Nieuwenhuizen W; Knot EA; Van Bergen PF; De Maat MP
Thromb Res; 1991 Feb; 61(4):441-52. PubMed ID: 1953861
[TBL] [Abstract][Full Text] [Related]
7. [Differentiation of fibrinolysis and fibrinogenolysis by analysis of FDP fragments].
Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Nakahata T; Saitoh H
Rinsho Byori; 1992 Jul; 40(7):789-94. PubMed ID: 1507499
[TBL] [Abstract][Full Text] [Related]
8. The fibrinogen degradation products (FgDP) levels in liver disease.
Song KS; Kim HS; Park KE; Kwon OH
Yonsei Med J; 1993 Sep; 34(3):234-8. PubMed ID: 8259700
[TBL] [Abstract][Full Text] [Related]
9. [Fluctuation of plasma levels of fibrinogen degradation products, fibrin degradation products and total fibrin/fibrinogen degradation products in patients with DIC].
Isogai N; Kuroso K; Fujimaki M; Yorifuji H; Fukutake K
Rinsho Byori; 1993 Dec; 41(12):1349-52. PubMed ID: 8295346
[TBL] [Abstract][Full Text] [Related]
10. Fibrinogen and fibrin degradation products in patients undergoing open-heart surgery.
Rifón J; Fernández J; Páramo JA; Cuesta B; Rocha E
Blood Coagul Fibrinolysis; 1990 Oct; 1(4-5):509-12. PubMed ID: 2133228
[TBL] [Abstract][Full Text] [Related]
11. Hemostatic imbalance in active and quiescent ulcerative colitis.
van Bodegraven AA; Schoorl M; Baak JP; Linskens RK; Bartels PC; Tuynman HA
Am J Gastroenterol; 2001 Feb; 96(2):487-93. PubMed ID: 11232695
[TBL] [Abstract][Full Text] [Related]
12. The effect of alcohol ingestion on the exercise-induced changes in fibrin and fibrinogen degradation products in man.
El-Sayed MS; Nieuwenhuizen W
Blood Coagul Fibrinolysis; 2000 Jun; 11(4):359-65. PubMed ID: 10847423
[TBL] [Abstract][Full Text] [Related]
13. Plasmin generation and fibrin(ogen)olysis following desmopressin infusion.
Takahashi H; Tatewaki W; Wada K; Niwano H; Hanano M; Shibata A
Am J Hematol; 1991 Apr; 36(4):255-8. PubMed ID: 1826408
[TBL] [Abstract][Full Text] [Related]
14. Is quantitative determination of fibrin(ogen) degradation products and thrombin-antithrombin III complexes useful to diagnose deep venous thrombosis in outpatients?
van Bergen PF; Knot EA; Jonker JJ; de Boer AC; de Maat MP
Thromb Haemost; 1989 Dec; 62(4):1043-5. PubMed ID: 2694421
[TBL] [Abstract][Full Text] [Related]
15. The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
Prentice CR; Hampton KK; Grant PJ; Nelson SR; Nieuwenhuizen W; Gaffney PJ
Br J Haematol; 1993 Feb; 83(2):276-81. PubMed ID: 8457476
[TBL] [Abstract][Full Text] [Related]
16. Activation of thrombosis and fibrinolysis following brain infarction.
Kataoka S; Hirose G; Hori A; Shirakawa T; Saigan T
J Neurol Sci; 2000 Dec; 181(1-2):82-8. PubMed ID: 11099716
[TBL] [Abstract][Full Text] [Related]
17. D-dimer and its relationship to fibrinogen/fibrin degradation products (FDPs) in disorders associated with activation of coagulation or fibrinolytic systems.
Moresco RN; Vargas LC; Voegeli CF; Santos RC
J Clin Lab Anal; 2003; 17(3):77-9. PubMed ID: 12696076
[TBL] [Abstract][Full Text] [Related]
18. An enzyme immunoassay for polymorphonuclear leucocyte-mediated fibrinogenolysis.
Bos R; van Leuven CJ; Stolk J; Hiemstra PS; Ronday HK; Nieuwenhuizen W
Eur J Clin Invest; 1997 Feb; 27(2):148-56. PubMed ID: 9061309
[TBL] [Abstract][Full Text] [Related]
19. Changes in the fibrinolytic system associated with physical conditioning.
De Paz JA; Lasierra J; Villa JG; Viladés E; Martín-Nuño MA; González-Gallego J
Eur J Appl Physiol Occup Physiol; 1992; 65(5):388-93. PubMed ID: 1425641
[TBL] [Abstract][Full Text] [Related]
20. Effects of tranexamic acid on fibrinolysis, fibrinogenolysis and amidolysis.
Takada A; Makino Y; Takada Y
Thromb Res; 1986 Apr; 42(1):39-47. PubMed ID: 3705023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
